No analyst coverage available for this stock.
idera pharmaceuticals is a clinical stage biotechnology company with expertise in discovering, developing and commercializing novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. idera is focused on harnessing the potential of our proprietary technology to treat genetically defined forms of b-cell lymphomas and rare autoimmune diseases.